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Different genotypes of avian paramyxovirus serotype-1 virus (APMV-1) circulate in many parts of the
world. Traditionally, Newcastle disease virus (NDV) is recognized as having two major divisions repre-
sented by classes I and II, with class II being further divided into sixteen genotypes. Although all NDV
are members of APMV-1 and are of one serotype, antigenic and genetic diversity is observed between
the different genotypes. Reports of vaccine failure from many countries and reports by our lab on the
reduced ability of classical vaccines to signiﬁcantly decrease viral replication and shedding have created
renewed interest in developing vaccines formulated with genotypes homologous to the virulent NDV
(vNDV) circulating in the ﬁeld. We assessed how the amount and speciﬁcity of humoral antibodies
induced by inactivated vaccines affected viral replication, clinical protection and evaluated how non-
homologous (heterologous) antibody levels induced by live NDV vaccines relate to transmission of vNDV.
In an experimental setting, all inactivated NDV vaccines protected birds from morbidity and mortality,
but higher and more speciﬁc levels of antibodies were required to signiﬁcantly decrease viral replication.
It was possible to signiﬁcantly decrease viral replication and shedding with high levels of antibodies and
those levels could be more easily reached with vaccines formulated with NDV of the same genotype as
the challenge viruses. However, when the levels of heterologous antibodies were sufﬁciently high, it
was possible to prevent transmission. As the level of humoral antibodies increase in vaccinated birds,
the number of infected birds and the amount of vNDV shed decreased. Thus, in an experimental setting
the effective levels of humoral antibodies could be increased by (1) increasing the homology of the vac-
cine to the challenge virus, or (2) allowing optimal time for the development of the immune response.
Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Infection of birds with virulent strains of Newcastle disease
virus (NDV) causes one of the most important infectious diseases
of poultry, Newcastle disease (ND), which is found worldwide
and leads to economic losses from mortality and condemnation
of carcasses. In 2010, seventy countries reported ND in
domestic species to the World Organization for Animal Health
(OIE) (www.oie.int.wahis/public.php?page=disease_status_lists)
and many countries have endemic NDV, with outbreaks occurring
year after year. Also known as avian paramyxovirus serotype-1
(APMV-1) virus, NDV is a member of the genus Avulavirus in the
Paramyxoviridae family (Mayo, 2002a,b).
Antigenic similarity is shared among all NDV strains and iso-
lates will cross-protect against challenge with any other NDV iso-late. It is this immunological stimulation that serves as the basis of
vaccination with live low virulent NDV (loNDV) to protect against
virulent NDV (vNDV). Genetically, ND viruses are diverse and six-
teen different genotypes have been already described (Courtney
et al., 2012; Diel et al., 2012). Early studies have shown antigenic
differences between strains of NDV using virus neutralization as-
says, hemagglutination inhibition (HI) assays with monoclonal
antibodies, and by evaluating sequences of neutralizing epitopes
(Panshin et al., 2002; Russell and Alexander, 1983; Schloer et al.,
1975). The antigenicity of classes and genotypes can also be differ-
entiated by cross HI assays, which correlate to differences in vac-
cine protection as measured by virus shedding after challenge
(Gu et al., 2011; Li et al., 2010; Miller et al., 2007, 2009). While
information regarding the avian immune response to NDV is
limited, both antibodies and cell-mediated immunity (CMI) play
a role in protection and clearance of NDV following infection
(Reynolds and Maraqa, 2000a,b). Antibodies can be detected
against NDV approximately 6–10 days post infection, while
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quire about 7–10 days. Because the mean death time following
infection with vNDV is 2–6 days, the presence of preexisting anti-
bodies prior to infection appear to be most critical to protection
from clinical disease (Kapczynski and King, 2005a). Antibodies pro-
duced against the hemagglutinin (HN) and fusion (F) trans-mem-
brane surface glycoproteins are able to neutralize NDV upon
subsequent infection (Boursnell et al., 1990a,b; Edbauer et al.,
1990). In contrast, CTLs help clear from the host cells that are al-
ready infected and cannot stop disease progression. Since the
pathology for loNDV is less than vNDV, the existence of preexisting
immunity is not as critical to inhibit disease, and makes them
excellent vaccine candidates.
Infection of chickens with vNDV results in rapid death of immu-
nologically naïve birds, and thus the contribution of cell-mediated
immunity is likely negligible since most birds are dead by 5–
10 days post inoculation (Kapczynski and King, 2005; Kapczynski
and Tumpey, 2003; Reynolds and Maraqa, 2000b). In contrast,
infection with loNDV strains in immunologically naïve birds re-
sults in a limited, local infection, in which both humoral antibodies
and antigen speciﬁc T-cells are generated. Clinical signs of infection
are generally not observed in limited infections with loNDV,
whereas the presence of secondary pathogens and/or immunosup-
pression can exacerbate clinical disease. In addition, mucosal
immunoglobulin A (IgA) is produced in the respiratory tract and
intestinal tract of chickens (Al-Garib et al., 2003a,b). Immunoglob-
ulin G (IgG) can also be detected on mucosal surfaces and is be-
lieved to contribute to the overall local immunity as well
(Chimeno Zoth et al., 2008). This mucosal antibody stimulation ap-
pears to aid in reduction of viral shedding, and will further aid in
reducing viral infection following secondary exposure to NDV.
Antibodies to the HN and F glycoprotein of NDV are critical for
virus neutralization and thus protection from vNDV (Reynolds and
Maraqa, 2000a). Antibodies against the HN are responsible for
blocking viral attachment, while antibodies against the F glycopro-
tein can inhibit viral fusion with the host cell membrane. Interest-
ingly, even low levels of antibodies can provide protection of
chickens against vNDV challenge (Gough and Allan, 1973).
Interest in the amount of vNDV shed into the environment by
vaccinated birds has arisen as a potential indicator of vaccine efﬁ-
cacy (Miller et al., 2007, 2009). The ND experiments have shown
that by using vaccines formulated with a NDV with the same
(homologous) genotype of the vNDV challenge virus, for both
genotype II and genotype V NDV isolates, it is possible to decrease
not only the number of birds shedding vNDV, but also the amount
of vNDV shed from individual birds by evaluating oropharyngeal
and cloacal swab material (Miller et al., 2007, 2009). However, in
those studies, the amount of virus shed from the birds vaccinated
with vaccines heterologous to the genotype of the challenge virus
was also decreased, but at lower amounts.
There is considerable controversy regarding the issue of vaccine
failure on NDV control. Some argue that vaccine failure is mainly
caused by inadequate application (Dortmans et al., 2012). How-
ever, others have suggested that vaccines formulated with geno-
types homologous to the genotype of the challenge virus that
reduce viral shedding should be a critical component of disease
control (Hu et al., 2011). It is unknown if the use of higher doses
of classical vaccines, which should induce higher antibody levels,
would be sufﬁcient to prevent ND caused by vNDV from genotypes
more distant from vaccine strains, or which genotypes are more
likely to fail vaccination with classical vaccines formulated with
genotypes I and II NDV strains. In addition, it remains to be
determined whether these older vaccines can signiﬁcantly reduce
viral shedding from challenge with newer isolates. In the present
study, we vaccinated birds with a live LaSota vaccine and then
challenged them with the heterologous vNDV (CA/2002) (deﬁnedas a virus of a different genotype) at different days post-vaccina-
tion (PV) to evaluate the amount of virus shed from each group
and to subsequently determine how successful that amount of
virus was transmitted to other birds. In addition, we further exam-
ined the seroconversion of chickens vaccinated with different
genotypes of inactivated NDV and challenged with homologous
and heterologous genotypes of vNDV to determine vaccine efﬁcacy
and humoral immunity on viral shedding. Our data indicate that
vaccination with NDV vaccines formulated with antigens homolo-
gous (of the same genotype) of the challenge virus signiﬁcantly re-
duces shedding compared to heterologous antigen, and that a
correlation exists between antibody response after challenge with
transmission potential to susceptible cohorts.2. Materials and methods
2.1. Viruses
Working stocks of virus isolates used were obtained from the
SEPRL repository and include US/LaSota/1946 (LaSota), gamefowl/
USA (California)/212676/2002 (CA/2002), poultry/Peru/1918-13/
2008 (Peru), Malaysia/1041/2008 (Malaysia) and Zoomat/Mexico
(Chiapas)/2010 (Mexico). All viruses were propagated in 9–11 days
old SPF embryos by chorioallantoic sac inoculation (Alexander and
Swayne, 1998). The virulent CA/2002 strain (genotype V) was iso-
lated as the etiological agent responsible for the last outbreak of
ND in the US. The widely used LaSota vaccine (genotype II) was
compared to recent vNDV viruses from Malaysia (genotype VIId),
Mexico (genotype V) and Peru (genotype XII), a novel and highly
divergent genotype related to recent African and Asian viruses in
vaccine efﬁcacy studies (Diel et al., 2012). Pools of infective allan-
toic ﬂuid were clariﬁed via centrifugation at 1000g for 15 min.
Infectivity titers of the pools were determined by titration in SPF
embryos prior to being stored at70 C for use as live vaccine virus
using hemagglutination (HA) assays.
2.2. Chickens and vaccine preparation
For all experiments, mixed-sex SPF chickens were obtained
from the Southeast Poultry Research Laboratory SPF ﬂocks and
transferred to a BSL2 or BSL3E facility for vaccination and a BSL3E
facility for challenge. Birds were maintained in Horsfal isolation
units with feed and water administered ad libitum. In experiment
II (below), four experimental NDV inactivated vaccines were pro-
duced with the LaSota, Mexico, Peru and Malaysia isolates follow-
ing growth in SPF eggs and harvesting of allantoic ﬂuid. Oil
emulsion-adjuvanted vaccines were prepared as described by
Stone et al. (1978). Following BPL-inactivation (Miller et al.,
2007) of allantoic ﬂuid, each vaccine virus was diluted to provide
a concentration of approximately 109.5 EID50/dose (0.5 ml). Sham
vaccine was prepared as above with normal allantoic ﬂuid har-
vested from SPF embryos.
2.3. Challenge experiment I
Birds were vaccinated with a live vaccine and challenged with
virulent CA/2002 at 3, 10 or 21 days post vaccination (Table 1).
Birds were given 100 ll of a live LaSota vaccine (106.5 EID50) with
half the dose given onto the right eye and the other half into the
choanal cleft. Sham vaccines for the controls and non-vaccinated
contacts consisted of sterile BHI and were given as described
above. The birds were challenged with the selected CA/2002 virus
with the speciﬁed (Table 1) mean 50% embryo infectious dose
(EID50) of 100 ll per bird, half administered in 50 ll into the right
eye and half in 50 ll into the choana. At 48 h post challenge, the 10
Table 1
Experimental design for experiment I demonstrating the difference in the time of
vaccination and challenge with vNDV CA/02 and the number of birds in each of the
groups.
Groupa # Birds/Group
1-Sham/C No vaccine/challenged 10
1-Con/Vax Vaccine/contactb 5
1-Con/NV No vaccine/contact 5
2–3dPV/C Challenged 3dPV 10
2-Con/3dPV Vaccine/contact 5
2-Con/NV No vaccine/contact 5
3–10dPV/C Challenged 10dPV 10
3-Con/10dPV Vaccine/contact 5
3-Con/NV No vaccine/contact 5
4–21dPV/C Challenged 21dPV 10
4-Con/21dPV Vaccine/contact 5
4-Con/NV No vaccine/contact 5
a C = Challenged; Con = Contact birds; dPV = days post vaccination; NV = Non-
vaccinated.
b Contact birds mixed with challenged birds at 2 days post-challenge.
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cal) and half were moved into a clean isolator with 5 vaccinated
contact (non-challenged birds) and 5 were moved into a clean iso-
lator with 5 non-vaccinated contact (non-challenged) birds. The
ﬂoors of the isolators were covered with paper to prevent fecal
matter from falling through the grated ﬂoor to allow access to
the contaminated feces, as it would be in a commercial setting
where birds are raised on the ﬂoor. Both the challenged and con-
tact birds were bled before vaccination and before challenge or
contact with challenged birds to evaluate antibody levels. 2 days
and 4 days after the challenged birds and contact birds were placed
into the same isolator, oropharyngeal and cloacal swabs were col-
lected from the challenged and contact birds into 1.5 ml of BHI
broth with a ﬁnal concentration of gentamicin (200 lg/ml), peni-
cillin G (2000 units/ml), and amphotericin B (4 lg/ml). Birds were
monitored daily for clinical signs and death through at least day 21
post-challenge when they were sedated, bled and euthanized.
Moribund chickens were euthanized with intravenous sodium
pentobarbital at a dose of 100 mg/kg and counted as dead on the
next day. This experiment was performed two times.2.4. Challenge experiment II
One hundred ﬁfty, 4 weeks old SPF chicks were randomly di-
vided in groups of 10 animals in BSL2 and vaccinated subcutaneous
with a single dose of each vaccine virus on the neck. The inacti-
vated vaccine strains included LaSota (genotype II), Mexico (geno-
type V), Malaysia (genotype VIId) and Peru (genotype XII). Serum
was collected and analyzed prior to vaccination to ensure the SPF
ﬂock was indeed NDV negative. A group of 10 birds remained
unvaccinated to serve as the sham-vaccinated control group for
each challenge virus. Clinical signs of NDV were monitored in all
groups daily for any vaccine reactions, which would be unlikely
for inactivated vaccines. At 3 weeks post vaccination prior to chal-
lenge, serum samples were collected for all animals and group of
birds were moved to BSL3 facility and challenged with homologous
and heterologous vNDV of different genotypes. The serum samples
were evaluated for NDV antibodies by hemagglutination inhibition
(HI) (Miller et al., 2007). Each group of chickens was challenged
with a different strain of vNDV corresponding to the selected geno-
types. Chickens were monitored for clinical signs daily and oral and
cloacal swabs were collected at day 4 post-challenge to evaluate
the amount of challenge virus shed from each bird. Morbidity
and mortality were followed for 2 weeks post-challenge. At the ter-
mination of the trial, serum was collected to measure post-infec-tion NDV antibody titers for all survivors. Humoral immunity
was evaluated by the HI test on serial 2-fold dilutions.2.5. Serology
Serum was obtained pre and post challenge from all birds and
tested by hemagglutination inhibition (HI) assay. The HI assay
was performed using inactivated NDV antigen according to stan-
dard procedures with 4 HAU virus/antigen in 0.025 ml (OIE,
2012). Titers were calculated as the highest reciprocal serum dilu-
tion providing complete hemagglutination inhibition. Serum titers
of 1:8 (23) or lower were considered negative for antibodies
against NDV.2.6. Virus shedding
Virus isolation (VI) was performed to identify virus shedding
conducted on oral and cloacal swabs as previously described (Mill-
er et al., 2007). All VI-positive swabs were titrated in 9–11 days old
SPF ECE as described (Alexander and Senne, 2008). Virus titers
were calculated using the Spearman–Kärber method (Kaerber,
1931) and were reported as mean embryo infectious dose (EID50/
0.1 ml) on a Log 10 scale.2.7. RNA extraction and sequencing
RNA extraction and sequencing was done as previously de-
scribed (Kim et al., 2007). Brieﬂy Total RNA was extracted by mix-
ing 250 ll of allantoic ﬂuid with 750 ll of Trizol LS reagent
(Invitrogen, Carlsbad, CA), following manufacturer’s instructions.
The fusion (F) gene was ampliﬁed by reverse transcription and
polymerase chain reaction (RT-PCR) using the SuperScript III
One-Step RT-PCR System with Platinum Taq DNA polymerase
(Invitrogen, Carlsbad, CA). Amplicons were sequenced with ﬂuo-
rescence dideoxynucleotide terminators in an ABI 3700 automated
sequencer (Applied Biosystems, Fosters City, CA). Assembly and
editing of sequencing data was performed using the DNASTAR La-
ser Gene software package, version 10.0. Sequences of Malaysia
and Mexico isolates have been sent to GenBank and the accession
numbers are KC808511, KF011206, and KF011207.2.8. Phylogenetics
Phylogenetic analysis was done by comparing the fusion pro-
tein. The evolutionary history was inferred by using the Maximum
Likelihood method based on the JTT matrix-based model (Jones
et al., 1992) (Fig. 1A). The tree with the highest log likelihood
(4489.0128) is shown. The percentage of trees in which the asso-
ciated taxa clustered together is shown next to the branches. Initial
tree(s) for the heuristic search were obtained automatically by
applying Neighbor-Join and BioNJ algorithms to a matrix of pair-
wise distances estimated using a JTT model, and then selecting
the topology with superior log likelihood value. A discrete Gamma
distribution was used to model evolutionary rate differences
among sites (4 categories (+G, parameter = 0.7050)). The rate vari-
ation model allowed for some sites to be evolutionarily invariable
([+I], 29.3614% sites). The tree is drawn to scale, with branch
lengths measured in the number of substitutions per site. The anal-
ysis involved 68 amino acid sequences. All positions containing
gaps and missing data were eliminated. There were a total of 550
positions in the ﬁnal dataset. Evolutionary analyses were con-
ducted in MEGA5 (Tamura et al., 2011).
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A
B
 LaSota  Mexico CA02  Peru    Malaysia 
LaSota    88.6  87.7  87.9 88.1  
Mexico 12.4    94.6  93.3 91.9  
CA02  13.5  10.5    90.8 89.9 
Peru  13.2  7.0  9.9   92.8 
Malaysia 12.7  8.3  10.5  7.2 
C
LaSota  Mexico CA02  Peru    Malaysia 
LaSota    88.1  89.0  86.7 86.9  
Mexico 12.8    94.8  89.7 89.7  
CA02  11.8  5.5    90.6 90.0 
Peru  14.5  11.1  10.1   90.7 
Malaysia 14.3  11.1  10.7  9.9 
Fig. 1. (A) Molecular Phylogenetic analysis of Newcastle Disease isolates by Maximum Likelihood method. Analysis of the full fusion protein was performed as described in
the Section 2. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis involved 68 amino acid sequences. All positions
containing gaps and missing data were eliminated. There were a total of 550 positions in the ﬁnal dataset. Evolutionary analyses were conducted in MEGA5 [2]. Virulent
viruses utilized in vaccination experiment are highlighted in yellow (virulent viruses) and vaccine viruses are highlighted in orange. (B) Fusion protein amino acid differences
between the LaSota and B1 vaccine viruses compared to selected vaccine and virulent challenge viruses. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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Kaplan–Meier survival curves were generated with Prism 5
(GraphPad Co., San Diego, CA). The Mantel–Cox log-rank test was
used to compare survival curves between two experimental groups(Prism 5). Statistical differences in mean and standard error be-
tween mean HI titers were analyzed using Tukey one-way ANOVA
(Prism 5). Lower case letters indicate statistical signiﬁcance be-
tween compared groups. All statistical tests were performed using
P < 0.05.
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3.1. Phylogenetics
All isolates used in these studies were compared using phylog-
enetics. Representative NDV strains of the most recent circulating
genotypes were selected for use as antigen in the inactivated vac-
cine experiment (Fig. 1A). Selection was based on phylogenetic dis-
tance and amino acid differences based on the NDV F gene. The
Peru (genotype XII) and Malaysia viruses (genotype VIId) represent
isolates from recent outbreaks in South America and Asia, and the
Mexico and CA/02 are representative of isolates of genotype V cir-
culating in North America.
Amino acid similarities for the key proteins involved in neutral-
izing NDV was determined by comparing the F and HN proteins of
ﬁeld isolates with the LaSota vaccine viruses using ClustalW with a
PAM250 matrix. The amino similarity at the fusion protein (upper
triangle) and percent divergence (lower triangle are represented)
are presented in Fig. 1B. In Fig. 1C a similar representation of the
comparison for the HN proteins is presented. The similarity be-
tween LaSota vaccine and circulating viruses varied between
87.7% and 88.6% for the F protein and between 86.7% and 89.0%
for the HN protein. Among current circulating viruses the similar-
ities varied between 89.9% and 94.6% for the F proteins, and be-
tween 89.7% and 94.8% for the HN proteins. This comparison
conﬁrms that the LaSota vaccine virus is more distantly related
to circulating viruses than these are among themselves.3.2. Protection from challenge in experiment I
The purpose of this study was to determine the role of the im-
mune response to a vaccine formulated with a NDV of a different
genotype than the genotype of the challenge virus on transmissi-
bility of vNDV in chickens infected at different times post-vaccina-
tion (Table 1). All of the non-vaccinated contact birds (Con/NV in
Groups 1, 2 and 3), which were placed with birds that were chal-
lenged before 21 days post-vaccination (PV), died between 4 and
19 days of contact (Fig. 2). Although all non vaccinated birds placed
into direct contact with directly challenge birds shed virus at day 2
post-contact, it is interesting to note that the level of shedding in
the contact groups (Groups 1–4 Con/NV) decreased as the time be-
tween vaccination and direct challenge increased from no vaccine
to 3, 10 and 21 days between vaccination and challenge (Table 2).
All of the vaccinated contact birds (Group 1-Con/3dPV, Group 2–
10dPV, and Group 3–21dPV) survived contact with the challenged0 5 10 15 20
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Fig. 2. Duration of protection and transmission following vaccination of chickens
with LaSota virus to lethal vNDV (CA/02) challenge. Birds vaccinated at various
intervals between challenge (0, 3, 10 and 21 days post-vaccination) were tested for
protection and contact (Con) shedding to vaccinated (Vax) and non-vaccinated (NV)
cohorts. The percent survival versus day post challenge was monitored for 21 days
following challenge or contact.birds. However, 75% of the birds in Group 1 Con/Vax did show
moderate to severe torticollis demonstrating transmission to this
group, and were humanly euthanized. The overall effect of increas-
ing the time between vaccination and challenge resulted in varia-
tion in the mortality from 40% at 3d (3dPV/C), 0% at 10d (10dPV/C),
and 0% at 21d (21dPV/C) (P < 0.05).
As the time between vaccination and challenge increased, the
amount of virus shed from the challenged birds also decreased
(Table 2). Additionally, with time there was only a small increase
in the antibody titers of the pre-challenge serum to the CA/02
antigen (Table 2). The HI antibody levels were negative in all birds
prior to challenge or contact with infected birds. The HI titers of
vaccinated birds of group 3 (3–10dPV/C and 3-Con/10dPV) pre-
challenge were 5.1 and 6.5 (log2), respectively (Table 2). The birds
in this group that were directly challenged demonstrated increased
HI titers (from 5.1 to 7.9), indicating virus replication, which was
observed as virus shedding in oral and cloacal swab samples
(Table 2). In contrast, no appreciable increase in HI titers [6.5–6.9
(log2)] was observed in the vaccinated contact birds placed in the
same isolator with the directly challenged birds. No virus was
recovered in oropharyngeal or cloacal swabs from these birds
2 days after these birds were mixed together with the vaccinated
birds directly challenged. Similar results between vaccinated-
challenged (21dPV) and contact vaccinated birds were observed
in Group 4 (Table 2) in that no virus was recovered from the
vaccinated contact birds 2 days after they were mixed with the
vaccinated directly challenged birds.
It is important to note that contact non-vaccinated birds in this
group did not become infected, shed virus or develop an antibody
response. The results demonstrate that as the days between vacci-
nation and challenge increase from 3 to 10 days or 21 days, the
percentage of non-vaccinated contact birds infected decreases
from 100%, 80% and 0%, respectively. As expected, when the LaSota
vaccine antigen was used in the HI assay, the pre-challenge anti-
bodies levels were found to be higher than the results obtained
when the same sera was tested with the challenge antigen, CA02
(Table 2).
3.3. Protection from challenge in experiment II
The purpose of this study was to investigate effect of inactivated
vaccine antigen on protection and shedding following homologous
or heterologous challenge. With one exception (80% survival in
Mexico NDV vaccine against Malaysia NDV challenge), survival
was 100% for vaccinated animals and mortality was 100% for
sham-vaccinated animals; however, not all challenge viruses
exhibited the same virulence (Fig. 3). For example, animals chal-
lenged with the Mexico or the Peru viruses demonstrated a mean
death time (MDT) of 3.5 days and 5 days, respectively. Unexpect-
edly, the Malaysia NDV strain caused a slow and uncharacteristic
mortality with MDT of 10 days. In terms of protection only the vac-
cine formulated with the Mexican antigen did not induce 100% sur-
vival against the Malaysian challenge. The uncharacteristic
behavior of the Malaysia virus is surprising and merits further
study.
All animals were negative for NDV HI antibodies at the begin-
ning of the experiment and all vaccines induced a signiﬁcant im-
mune response (Table 3). HI antibody titers for all vaccine groups
were determined to be between 6 and 7 (log2) with the LaSota anti-
gen, but the titers increased when the antigen used in the vaccine
was used in the HI assay. In the LaSota-vaccinated animals, a rise in
antibody titers was observed after challenge with each isolate, sug-
gesting that challenge virus replication was not completely pre-
vented by the vaccination protocol. This group demonstrated the
highest average change between pre- and post-challenge titers
than the other groups. In the animals vaccinated with the Malaysia
Table 2
Serology and virus shedding in Experiment I. Pre- and post-challenge HI antibody titers (log2) to the CA/02 virus are shown. Viral titers (log10) expressed as mean embryo
infectious doses per 0.1 ml from oral and cloacal swabs taken at day 2 post-challenge for the challenged birds (C) or post-contact for the contact birds (Con).
Groupa Pre/Post Challenge HI titerb Viral load in swab samples taken at day 2 post-challenge or post contact with challenged birds
LaSota Antigen CA02 Antigen Oral Cloacal
1-Sham/C <2/NS <2/NS 6.6 5.4
1-Conc/Vax <2/NS <2/NS 5.1 4.0
1-Con/NV <2/NS <2/NS 5.0 4.1
2–3dPV/C <2/9.7 <2/9.7 3.7 4.2
2-Con/3dPV <2/6.0 <2/7.1 1.7 1.1
2-Con/NV <2/NS <2/NS 4.5 3.5
3–10dPV/C 8.3/7.5 5.1/7.9 2.3 0.5
3-Con/10dPV 8.1/5.2 6.5/6.9 0 0
3-Con/NV <2/NS <2/NS 2.9 1.5
4–21dPV/C 6.8/9.1 5.4/8.2 0.6 0
4-Con/21dPV 6.7/6.0 5.2/6.0 0 0
4-Con/NV <2/<2 <2/2 0 0
a C = Challenged; Con = Contact birds; dPV = days post vaccination; NV = Non-vaccinated; Vax = vaccinated at different times prior to introduction of infected birds.
b Birds vaccinated with LaSota vaccine with titers obtained with the LaSota and CA/02 antigens.
c Contact birds mixed with challenged birds at 2 days post-challenge.
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Fig. 3. Homologous versus heterologous vaccination and challenge against recent
vNDV isolates. Birds were vaccinated with various vaccine antigens (LaSota,
Malaysia, Mexico, or Peru) and challenged with homologous or heterologous vNDV
(Malaysia, Mexico, or Peru). Three weeks post-vaccination birds were challenged
with lethal vNDV and the percent survival was monitored for 14 days.
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batches challenged with Malaysia, Mexico, and Peru, respectively.
In the groups of animals vaccinated with the Mexico NDV strain,
the homologous pre-challenge titers were 7.0, 8.6, and 7.0 for ani-
mals to be challenged with Malaysia, Mexico, and Peru, respec-
tively. No signiﬁcant increase in HI titers was observed after
challenges with Peru or Mexico; however, a signiﬁcant increase
was observed in the animals infected with the Malaysia NDV iso-
late. The lack of a signiﬁcant increase in HI titers observed after
challenges with Peru and Mexico suggest that those vaccines likely
prevented virus replication after challenge with the homologous
NDV strain. However, the homologous challenge with the MalaysiaTable 3
Pre- and post-challenge HI antibody titers (log2) to the homologous and heterologous antig
are bolded. The post challenge titers are in parenthesis to the right of the pre-challenge a
Serum vaccine groups HI Antigen
LaSota Malaysia Difference
LaSota 6.6 5.5 (8.6) 3.06
Malaysia 6.0 9.2 (10) 0.83
Mexico 6.8 7.0 (10.3) 3.20
Peru 6.1 5.5 (7.4) 1.9vaccinated birds produced a signiﬁcant increase in titers. In the
animals vaccinated with Peru, the pre-challenge titers were 5.5,
5.3 and 6.2, for the animals challenged with Malaysia, Mexico,
and Peru, respectively. This was the only group in which pre-chal-
lenge titers were not the highest against the homologous virus. In
all cases, the antibody titers increased post-challenge, again sug-
gesting that those vaccines did allow some viral replication.
Virus shedding in oropharyngeal swabs was signiﬁcantly re-
duced in homologous vaccinated-challenged animals compared
to sham-vaccinated (control) birds for two of the three challenge
viruses (Fig. 4). A 4-log reduction in titer was observed in the
Malaysia-vaccinated/Malaysia challenged group compared to
sham-vaccinated birds, whereas the Malaysia-vaccinated/Malay-
sia-challenged group demonstrated an approximate 1.5-fold
reduction compared to heterologous-vaccinated/Malaysia-
challenged groups. A similar pattern was observed with the
Mexico-vaccinated/Mexican-challenged birds, as well. Homolo-
gous vaccinated birds demonstrated a 5-log reduction from
sham-vaccinated birds, and a 2-log reduction from heterologous-
vaccinated/Mexico-challenged birds. In contrast, all vaccinated
birds (both homologous and heterologous vaccines) challenged
with the Peru virus demonstrated a similar level of reduced shed-
ding, approximately 2-fold compared to the sham-vaccinated/
Peru-challenged birds, with no signiﬁcant difference observed
between the vaccine groups. All vaccines signiﬁcantly reduced shed-
ding in cloacal swabs compared to sham-vaccinated birds but no sig-
niﬁcant differences were obtained when comparing the amount of
virus shed between the different vaccines (data not shown).3.4. Correlation of humoral response and shedding
To test the effects of the humoral immune response to viral
shedding in surviving birds, we correlated the difference in HIens used in Experiment II. Titers homologous between the vaccine and challenge virus
ntibody titers.
Mexico Difference Peru Difference
5.7 (8.1) 2.37 6.5 (7.9) 1.48
6.4 (8) 1.56 6.8 (8.8) 2.00
8.6 (8.6) 0.00 7.0 (7.9) 0.90
5.3 (7.3) 2.0 6.2 (8.3) 2.06
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Fig. 4. Viral titers obtained from oral swabs on day 4 post-challenge in experiment
II. Birds were vaccinated at 2 weeks of age and challenged with homologous or
heterologous virus at 5 weeks of age.
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In experiment I, a strong correlation (0.78) was observed between
groups of surviving birds when viral shedding titers were com-
pared to antibody response (Fig. 5A). In these comparisons, contact
birds from groups 3-Con/10dPV, 4-Con/NV, and 4-Con/21dPV did
not shed virus and had no change in HI response. The relationship
was conﬁrmed with birds shedding various levels of virus (be-
tween 0.6 and 3.6 log10 EID50/0.1 ml), and a relative gain in anti-
body response. Of note is the observation that when challenge
was applied early after vaccination, a higher level of shedding
was observed (e.g. Group 2–3dPV/C) than groups challenged later
after vaccination (e.g. 3–10dPV/c or 4–21dPV/C). In the second rep-
lication of this experiment one bird from group 4–21dPV/C was in-
fected and did have an anamnestic response in HI titer. In
experiment II a linear correlation (0.691) was also observed be-
tween the surviving groups (Fig. 5B). As expected, groups of vacci-
nated birds challenged with homologous vNDV exhibited low
amounts of virus shedding, which resulted in little to no change
in HI titer. In contrast, vaccinated birds challenged with heterolo-
gous virus demonstrated greater changes in HI titers and higher
levels of virus shedding.4. Discussion
The study of the transmission of Newcastle disease virus has
been and continues to be a relevant topic for the poultry industry
as it is important for understanding not only how to prevent the
spread of vNDV, but also how to enhance protection of mass-vac-
cinated ﬂocks (Delay, 1948; Estola et al., 1979; Li et al., 2009). In
addition to airborne transmission, NDV can spread though direct
contact with infected birds, contaminated poultry products con-
sumed by other birds, people with contaminated clothes or shoes,
equipment or vaccines (Alexander, 1988). Infection from ingestion
of contaminated feed (Alexander et al., 1984), water (Saber et al.,
1978) and ﬂies found in a poultry house (Chakrabarti et al.,
2007) may also occur. It is possible, and likely, that more than
one of the aforementioned factors would contribute to the spread
and transmission of NDV among birds depending on each situation.
Like most vaccines, NDV vaccines do not prevent vaccinated
animals from becoming infected with a vNDV and subsequently
shedding the virus (Kapczynski and King, 2005). However, most
vaccines will signiﬁcantly decrease the amount of virus shed insaliva and feces compared to non-vaccinated birds (Miller et al.,
2009). The amount shed will depend on the immunity of the host,
the host species infected, the amount and virulence of the chal-
lenge virus, the dose and type of ND vaccine and the time between
vaccination and challenge. While the amount will vary depending
on the NDV isolate and the host species, it is thought that (under
experimental conditions) each host would need to receive between
103 and 104 EID50 of virus to become infected with NDV (Alexander
et al., 1999; King, 1996). With these and previous experiments
(Miller et al., 2009) using LaSota vaccine and CA/2002 challenge
virus the question remained as to if the amount of virus shed
would be enough to infect other naïve and vaccinated birds.
Unfortunately, due to the requirements of working with vNDV
in an isolator with a HEPA ﬁlter and in a room with negative pres-
sure, and necessary air exchanges, our experimental conditions are
likely to be dissimilar than those found in the ﬁeld. However, even
with 12 air exchanges per hour, which would signiﬁcantly decrease
the amount of available aerosolized virus, we were able to get
transmission to almost all of the non-vaccinated contact birds
when they were placed into isolators with sub-optimally vacci-
nated or non-vaccinated challenged birds. In this experimental set-
ting, with SPF birds, the LaSota vaccine provided 100% protection
against clinical disease and death at 10 days post vaccination chal-
lenge. Interestingly, none of the non-vaccinated contact birds be-
came infected when mixed with the birds challenged 21 days PV.
This highlights the importance of (1) having enough time between
vaccination and challenge to develop sufﬁcient immunity and (2)
the importance of ﬂock (herd) immunity in the protection con-
ferred with vaccines (van Boven et al., 2008).
A similar result was observed with challenges at 10 days PV.
The vaccinated contact birds were not infected, but the naïve
non-vaccinated birds were infected. The environmental contami-
nation that exists in an outbreak setting and/or with any vacci-
nated population should be taken into consideration for
Newcastle disease control. This is especially true of countries with
endemic vNDV. For each country, it is important to know the char-
acteristics and virulence of the vNDV circulating and which vac-
cines provide the largest decrease in vNDV shed so that less
vNDV is put into the environment. While all NDV isolates are of
one serotype, some strains (antigens) that used to circulate are
no longer found in some areas of the world (Miller et al., 2010).
As demonstrated here, even small amounts of vNDV shed by birds
vaccinated with the LaSota vaccine may pass to other vaccinated
birds if ﬂock immunity is low. However, when ﬂock immunity in-
creases, even low levels of antibody titers may be sufﬁcient to pre-
vent infection depending on the challenge dose. Another important
point of this study is that the differences in immune responses ob-
served between day 3, 10 and 21 seem to be very critical as a deter-
minant of transmission, thus suggesting that even heterologous
vaccines can prevent transmission if sufﬁcient time is allowed for
birds to mount a proper immune response. Furthermore, the long
delay of 21 days to achieve suppression of transmission suggests
that future studies on vaccination should focus on ways to acceler-
ate speed of the immune response in addition to the use of homol-
ogous antigens.
Despite of the use of an equal amount of antigen in experiment
II, not all inactivated vaccines produced the same levels of pre-
challenge humoral antibodies. The factors involved in those
different responses are currently unknown. The LaSota and Peru
vaccines induced the lowest pre-challenge antibody levels. How-
ever, even for these vaccines there was, in most cases, 100% protec-
tion against mortality and clinical signs. Overall, the increase in
antibody titers post-challenge for the LaSota and Peru vaccines
indirectly suggests that these vaccines may be not be as effective
in protecting against viral replication as they are of protecting
against clinical signs, and perhaps that homology is important.
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Fig. 5. Correlation between antibody response and viral shedding in Experiments I (A) and II (B). The change in HI antibody response between pre- and post-challenge was
plotted against corresponding mean virus shedding for that group. The relative correlation between the data points is given by R-value. (B) Each point is represented by the
vaccine antigen (ﬁrst letter) and challenge virus (second letter) with L = LaSota, M = Malaysia, Mx = Mexico, P = Peru.
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lenge antibody levels. Birds vaccinated with these antigens did not
produce a signiﬁcant increase in antibody titers after challenges,
suggesting that a high threshold of humoral immunity can reduce
viral replication, independent of genotype of the vaccine. These
data are in agreement with recently published data for viruses of
genotype VIId showing that a live heterologous LaSota vaccine
was not effective in preventing viral replication at clinically protec-
tive doses (103 to 105) (Cornax et al., 2012). However, if the vaccine
dose was sufﬁciently high (106 to 108 EID50/bird) virus replication
(measured indirectly as post challenges increases in antibody ti-
ters) was prevented. The surprisingly partial protection of Mexico
against Malaysia, and the unusual behavior of the Malaysia viruseson the sham-vaccinated animals, suggests that further studies
need to be done to characterize the Malaysian viruses.
Results in Fig. 1A–C conﬁrm that observed genomic distances
correlate with amino acid differences in the F and HN proteins.
However, these differences in amino acid identity are large and a
simple amino acid comparison is not likely to be a sufﬁcient indi-
cator of antigenic similarities, suggesting that the selection of vac-
cine antigens still will have to be done based on empirical cross
protection studies with live animals. It is interesting to note that
there seems to be an increased genetic variability in HN in compar-
ison with the F protein; however, it is still too early to predict if any
of those genes are going to be suitable predictors of cross protec-
tion. One would expect the antigens with the least HN genome
P.J. Miller et al. / Developmental and Comparative Immunology 41 (2013) 505–513 513similarities (Fig. 1C) to produce the worst HI results (Table 3), but
this only occurred for the birds vaccinated with the Mexican and
Malaysian antigens.
Virulent NDV continues to be endemic in many countries
around the world despite the application of billions of doses of live,
inactivated, and recombinant NDV vaccines. Our studies indicate
that matched vaccines to ﬁeld isolates have potential to provide
superior protection against transmission by reducing the magni-
tude of viral shedding. In the ﬁeld, multiple factors may decrease
the effectiveness of vaccination thus making the antibody speciﬁc-
ity more important. Further investigation as to the best vaccine for
individual situations, focusing not only on prevention of clinical
disease and mortality, but also on decreasing the amount of virus
shed from vaccinated birds is an important consideration in coun-
tries with endemic vNDV.
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